ArticleCureus2025
Fluoxetine and Paroxetine Exhibit a Protective Effect Against Total Joint Arthroplasty in Patients With Osteoarthritis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Recent research has elucidated the biochemical mechanism by which some selective serotonin reuptake inhibitor (SSRI) drugs, fluoxetine and paroxetine, slow osteoarthritis (OA) disease progression. This novel study aimed to evaluate the impact of fluoxetine and paroxetine on the risk of undergoing primary total hip (THA) or knee arthroplasty (TKA) among OA patients. Methods A retrospective cohort study using the TriNetX network compared OA patients prescribed fluoxetine (n=2478) or paroxetine (n=1500) to matched controls without SSRI exposure. Outcomes were assessed via risk analysis, Kaplan-Meier survival analysis, and hazard ratios (HR). Results The absolute risk of needing THA or TKA was significantly lower in both SSRI cohorts compared to matched controls. In the fluoxetine cohort, the relative risk (RR) of undergoing THA or TKA was 0.678 (95% CI: 0.645-0.713), while in the paroxetine cohort, it was 0.791 (95% CI: 0.740-0.845). The fluoxetine cohort had an 8.22% chance of requiring total joint arthroplasty (TJA), compared to 14.15% in controls. The paroxetine cohort had an 8.14% chance versus 8.46% in controls. This corresponds to a 1.1% absolute reduction in risk for fluoxetine (95% CI: 1.0-1.3%, p<0.0001) and a 0.7% reduction for paroxetine (95% CI: 0.5-0.9%, p<0.0001). The fluoxetine cohort had a hazard ratio (HR) of 0.675 (95% CI: 0.642-0.711, p<0.0001), while the paroxetine cohort had an HR of 0.742 (95% CI: 0.694-0.794, p<0.0001). Conclusion Patients prescribed either paroxetine or fluoxetine had a statistically significant decrease in risk of undergoing THA or TKA; however, further research is needed to explore other clinical outcomes and therapeutic benefits of SSRIs in OA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.